secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-278805
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio Q3 net loss $7.4M; completes Part B enrollment in SIGNAL-AA; cash runway into 2027
--------------------------------------------------------------------------------

- Completed enrollment in Part B of SIGNAL-AA Phase 2a trial for alopecia areata; trial size increased to 33 patients; topline data expected mid-2026.
- Cash and equivalents $49.0M as of Sep 30, 2025, expected to fund operations into 2027.
- Net loss $7.4M ($0.60 per share) vs $17.6M ($1.46 per share) in Q3 2024, driven by lower R&D spend.
- R&D expenses decreased to $3.6M from $14.3M; G&A to $4.0M from $4.5M year-over-year.
- Emerging signs of clinical activity observed; preliminary PK shows steady-state drug concentration achieved 9 weeks earlier with loading regimen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525278805/0001193125-25-278805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312525278805/qttb-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-278805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer